WHO okays antibody treatment for high risk COVID-19 patients: BMJ

Written By :  Dr Kartikeya Kohli
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2021-09-24 01:30 GMT   |   Update On 2021-09-24 07:01 GMT
Advertisement

WHO Guideline Development Group (GDG) panel of international experts and patients has recommended a treatment combining two antibodies (casirivimab and imdevimab) for two specific groups of patient0s with covid-19 namely high risk of hospital admission and for severely ill patients who have no natural antibodies to covid-19.

The guideline has been published in The BMJ today.

The first recommendation is based on new evidence from three trials that have not yet been peer reviewed, but show that casirivimab and imdevimab probably reduce the risk of hospitalisation and duration of symptoms in those at highest risk of severe disease, such as unvaccinated, older, or immunosuppressed patients.

Advertisement

This second recommendation is based on data from the RECOVERY trial showing that casirivimab and imdevimab probably reduce deaths (ranging from 49 fewer per 1,000 in the severely ill to 87 fewer in the critically ill) and the need for mechanical ventilation in seronegative patients.

For all other covid-19 patients, any benefits of this antibody treatment are unlikely to be meaningful.

Casirivimab and imdevimab are monoclonal antibodies that when used together bind to the SARS-CoV-2 spike protein, neutralising the virus's ability to infect cells.

The recommendations are part of a living guideline, developed by the World Health Organization with the methodological support of MAGIC Evidence Ecosystem Foundation, to provide up to date, trustworthy guidance on the management of covid-19 and help doctors make better decisions with their patients.

Living guidelines are useful in fast moving research areas like covid-19 because they allow researchers to update previously vetted and peer reviewed evidence summaries as new information becomes available.

The panel acknowledged several cost and resource implications associated with this treatment, which may make access to low and middle income countries challenging. For example, rapid serological tests will be needed to identify eligible patients who are severely ill, treatment must be given intravenously using specialist equipment, and patients should be monitored for allergic reactions.

They also recognise the possibility that new variants may emerge in which casirivimab and imdevimab antibodies may have reduced effect.

However, they say given the demonstrated benefits for patients, "the recommendations should provide a stimulus to engage all possible mechanisms to improve global access to the intervention and associated testing."

Today's guidance adds to previous recommendations for the use of interleukin-6 receptor blockers and systemic corticosteroids for patients with severe or critical covid-19; and against the use of ivermectin and hydroxychloroquine in patients with covid-19 regardless of disease severity.

Public link once embargo lifts: https://www.bmj.com/content/370/bmj.m3379


Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News